Literature DB >> 23060726

Excision with corneoscleral lamellar keratoplasty and amniotic membrane transplantation of a corneal displaced recurrent conjunctival melanoma.

Eun Chul Kim1, Man Soo Kim, Nam Yeo Kang.   

Abstract

An 81-year-old woman with a raised pigmented nodule over her left cornea for 7 months duration was examined. Dark conjunctival pigmentation was observed in the upper bulbar fornix conjunctiva. She had previously undergone primary surgical excision of a malignant conjunctival melanoma four years earlier. The tumor separated easily from the corneal surface, but remained slightly attached to the corneoscleral surface. A corneoscleral lamellar dissection of 3 mm in width and 2 mm in depth as well as a corneoscleral lamellar keratoplasty for the reconstruction of the corneoscleral defect were performed. The wide upper bulbar and fornix conjunctiva were excised, and an amniotic membrane transplantation was performed. Biopsy revealed an invasive melanoma with a depth of 1 mm. Left, right, and inferior tumor margins of the corneoscleral lesion and the pigmentary lesion in the conjunctiva were free of the tumor. After surgery, 0.04% mitomycin was administered topically 4 times daily for 4 weeks. There was no recurrence 2 years after surgery, and systemic evaluation revealed no metastasis.

Entities:  

Keywords:  Amniotic membrane; Lamellar keratoplasty; Malignant melanoma

Mesh:

Year:  2012        PMID: 23060726      PMCID: PMC3464323          DOI: 10.3341/kjo.2012.26.5.383

Source DB:  PubMed          Journal:  Korean J Ophthalmol        ISSN: 1011-8942


  18 in total

Review 1.  Role of topical chemotherapy for primary acquired melanosis and malignant melanoma of the conjunctiva and cornea: review of the evidence and recommendations for treatment.

Authors:  Rajeev Chalasani; Michael Giblin; R Max Conway
Journal:  Clin Exp Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 4.207

2.  Topical mitomycin chemotherapy for malignant conjunctival and corneal neoplasia.

Authors:  P T Finger
Journal:  Br J Ophthalmol       Date:  2006-07       Impact factor: 4.638

Review 3.  Clinical aspects of conjunctival melanoma.

Authors:  Christopher Layton; William Glasson
Journal:  Clin Exp Ophthalmol       Date:  2002-04       Impact factor: 4.207

4.  Reconstruction of conjunctiva with amniotic membrane after excision of large conjunctival melanoma: a long-term study.

Authors:  G Dalla Pozza; A Ghirlando; F Busato; E Midena
Journal:  Eur J Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 2.597

5.  Amniotic membrane transplantation in the management of conjunctival malignant melanoma and primary acquired melanosis with atypia.

Authors:  D Paridaens; H Beekhuis; W van Den Bosch; L Remeyer; G Melles
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

6.  Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study.

Authors:  Gerasimos Anastassiou; Arnd Heiligenhaus; Nikos Bechrakis; Elisabeth Bader; Norbert Bornfeld; Klaus-Peter Steuhl
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

7.  Malignant melanoma of the conjunctiva with intraocular extension.

Authors:  H Wenkel; V Rummelt; G O Naumann
Journal:  Arch Ophthalmol       Date:  2000-04

8.  Malignant epibulbar melanoma: natural history and treatment by radiotherapy.

Authors:  M Lederman; K Wybar; E Busby
Journal:  Br J Ophthalmol       Date:  1984-09       Impact factor: 4.638

9.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09

10.  Surgical management of circumscribed conjunctival melanomas.

Authors:  J A Shields; C L Shields; P De Potter
Journal:  Ophthalmic Plast Reconstr Surg       Date:  1998-05       Impact factor: 1.746

View more
  1 in total

Review 1.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.